Background: Some of the disagreements on the perception of dyspnea (PD) during bronchoconstriction in asthma patients could depend on the interrelationships among the following: (1) the influence of baseline airflow obstruction on the patient's ability to detect any further increase in airway resistance; (2) the effect of eosinophilic inflammation on the airway; (3) bronchial hyperresponsiveness (BHR); and (4) the effect of inhaled corticosteroids (ICSs). Objective: We hypothesized that if the inflammation of the airway wall influences to some extent and in some way the PD in asthma patients, ICSs reverse the effect of airway inflammation on the PD. Methods: We studied 100 asthma patients who were divided into the following four groups: patients with obstruction who were either ICS-naive (group I) or were treated with ICSs (group II); and nonobstructed patients who were either ICS-naive (group III) or were treated with ICSs (group IV). PD on the visual analog scale (VAS) was assessed during a methacholine-induced FEV 1 decrease and specifically was quantified as the VAS slope and score at an FEV 1 decrease of 5 to 20%. BHR was assessed in terms of the provocative concentration of methacholine causing a 20% fall in FEV 1 (PC 20 ). Eosinophil counts in induced sputum samples also were performed. Regression analysis, univariate analysis of variance, and factor analysis were applied for statistical evaluation. 
D
yspnea has a multifactorial nature, 1 and the exact mechanism that causes breathlessness in asthma is not fully understood. Mechanical factors including rib cage inspiratory muscle activation, 2-4 pulmonary hyperinflation, 5 temporal adaptation, [6] [7] [8] bronchial hyperresponsiveness (BHR), 6 psychological factors, 9 or emotional and cognitive factors, 10 have been proposed to influence the perception of dyspnea (PD) during bronchoconstriction in asthma patients. Furthermore, the role of inflammation and anti-inflammatory treatment in the modulation of the PD has recently been investigated. [11] [12] [13] [14] PD related negatively to eosinophilic airway inflammation in patients with mild-to-moderate asthma 13 as well as in patients with severe asthma. 14 This would explain the beneficial influence of anti-inflammatory treatment with inhaled corticosteroids (ICSs) on PD observed in patients with mild-tomoderate asthma. 11, 13 However, studies 12, 14 on the effect of ICSs on PD have provided conflicting results. The severity of the disease, despite ICS therapy, has been advocated as an explanation for the observation that eosinophilic airway inflammation directly impairs PD, 14 even if a direct central effect of ICS therapy on acuity of perception has not been excluded. 12, 14 Thus, it has not been clearly understood why ICSs, which act by modulating airway inflammation, 15 may be associated with either a decreased or an increased PD. In addition, the observation that ICSs may lessen PD has been reported in patients with mild-to-moderate asthma 12 as well as in patients with severe asthma, 14 while increased PD has been observed in patients with mild-to-moderate asthma, 11, 13 leaving the relationships unclear.
Based on the above findings, we hypothesized that if the inflammation of the airway wall to some extent and in some way influences the PD in asthma patients, then ICS therapy may reverse the effect of airway inflammation on PD.
In patients with asthma, Rubinfeld and Pain 8 showed that deteriorating airway function may increase the perception of acute exacerbation, and Burdon et al 6 showed that patients with airway obstruction had a similar degree of breathlessness as patients without airway obstruction, only at a point when they were considerably more obstructed. Ottanelli et al 7 have shown recently a decreased perception of acute exacerbation in patients with initial airflow obstruction compared to those without airway obstruction. The apparent discrepancy between the results of the studies of Ottanelli et al 7 and Burdon et al 6 is likely to be due to the different levels of induced obstruction, which are greater in the latter study than in the former. Nevertheless, in both cases temporal adaptation, which dictates the high threshold for the perception of acute lung change, 6 was considered to be the reason for the different responses in obstructed and nonobstructed patients.
Therefore, the present investigation was carried out in ICS-naive and ICS-treated asthma patients with or without airway obstruction, and with different levels of both BHR and airway inflammation.
Materials and Methods

Patients
One hundred asthma patients (65 women) aged 16 to 75 years (mean age, 41.5 years) diagnosed with bronchial asthma according to the criteria of the National Heart, Lung, and Blood Institute 16 participated in the study. In all patients, asthma was stable and persistent, and it was classified as either mild or mild to moderate according to the frequency of symptoms, the requirement of ␤ 2 -agonists for the treatment of symptoms, baseline airway function, BHR, and a provocative concentration of methacholine causing a 20% fall in FEV 1 (PC 20 ) Ͻ 8 mg/mL. No patients had a history of smoking. In 74 patients, skin prick test responses were positive for a common panel of aeroallergen extracts. Subjects sensitized to pollens were studied out of the relevant season. The duration of disease ranged from 1 month to 20 years. Each patient was in a clinically stable condition at the time of the study (ie, stability in FEV 1 and domiciliary peak flow measurements, and constancy of ␤ 2 -agonist response). According to their FEV 1 /vital capacity (VC) percentage ratio, patients were divided into obstructed and nonobstructed, with the cutoff being set at a FEV 1 /VC percentage ratio of 70%. 17 Forty-nine patients had airway obstruction, of whom 19 were ICS-naive and 30 were ICS-treated. Fifty-one patients were nonobstructed, of whom 26 were ICS-naive and 25 were ICS-treated. Therefore, we studied the following four groups: obstructed ICS-naive patients (group I); obstructed ICS-treated patients (group II); nonobstructed ICS-naive patients (group III); or nonobstructed ICS-treated patients (group IV). All treatment with bronchodilators was withheld for at least 12 h before the start of the study. All patients had been free from acute respiratory tract infections during the preceding 4 weeks. Informed consent was given by each patient, and the study was approved by the local ethics committee.
Clinical Scores
Degree of asthma severity was assessed by a modified version of the asthma severity score proposed by Brooks et al. 18 Possible scores ranged from 0 to 20. The asthma severity score was based on the following: (1) the frequency of attacks of wheezing and/or chest tightness that occurred during an average day, scored from 0 to 4 (0, none; 1, two attacks per year; 2, monthly attacks; 3, weekly attacks; 4, daily attacks); (2) the frequency of asthma attacks that awoke the patient at night, scored from 0 to 4 (0, none; 1, two attacks per year; 2, monthly attacks; 3, weekly attacks; 4, daily attacks); (3) chronic exertional dyspnea (from the modified Medical Research Council dyspnea scale, 19 scored from 0 [no breathlessness] to 4 [breathlessness during dressing or undressing]); (4) treatment required to control asthma, scored from 0 to 4 (0, none or ␤ 2 -agonist bronchodilators received 1 or 2 times per year; 1, bronchodilators received intermittently only; 2, bronchodilators received daily; 3, bronchodilators received in association with ICSs; 4, oral corticosteroids received); and (5) frequency of cough, scored from 0 to 4 (0, no cough; 1, two attacks per year; 2, monthly episodes; 3, weekly episodes; 4, daily episodes).
Measurements
Lung Function: Baseline pulmonary function testing was performed by measuring static and dynamic lung volumes with a water-sealed spirometer (Pulmonet Godart; SensorMedics Corp; Yorba Linda, CA), as previously reported. 20 The normal values for lung volumes are those proposed by the European Community for Coal and Steel. 21 Bronchial Challenge: Each patient was administered a methacholine aerosol inhalation test according to a standardized tidal breathing procedure. 22 Increasing concentrations of methacholine-chlorhydrate in normal phosphate-buffered saline solution (prepared by the University Hospital Pharmacy) were inhaled from a nebulizer (model 646; DeVilbiss Co; Somerset, PA), resulting in an output of 0.13 mL/min. With this method, 4 mL of solution was placed in the nebulizer, and inhalation continued during tidal breathing for 2 min. The methacholine solution was stored at 4°C and was nebulized at room temperature. Normal phosphate-buffered saline solution was inhaled first, followed at 5-min intervals by methacholine in twofold increasing concentrations from 0.015 to 8 mg/mL. The test was withheld at the PC 20 . FEV 1 was measured 1 to 1.5 min after the inhalation of each concentration of methacholine. Two measurements of FEV 1 were performed, and the best value was used. The PC 20 was noted from the log dose-response curve. The log cumulative dose of methacholine also was calculated for each patient. Dyspnea: Dyspnea was described to the patients as nonspecific discomfort associated with the act of breathing. This was chosen as a global expression to encompass all uncomfortable stimuli and their associated sensations. 23 The PD during methacholineinduced bronchoconstriction was evaluated by administering each patient a visual analog scale (VAS) before the first inhalation and just after the inhalation of each concentration of methacholine and before FEV 1 measurement. 5, 6, 11, 24 The VAS scale is a horizontal 10-cm line labeled "no breathlessness at all" at the left end and "the worst breathlessness ever experienced" at the right end. The subjects were asked to place a vertical mark on the horizontal line. The VAS dyspnea score was expressed as the distance of the mark from the left end of the VAS in millimeters. 24 We also recommended that patients rate only dyspnea and that they ignore other sensations such as irritating cough, throat irritation, headache, or pharyngitis. During the test, the subjects were blinded to their lung function responses.
Induction of Sputum: The induction of sputum was performed according to the method of Ronchi et al. 25 Briefly, 10 min after fenoterol inhalation (200 g), hypertonic saline solution was nebulized with an ultrasonic nebulizer (Fisoneb; Fisons Corp; Rochester, NY) and was inhaled for 5-min periods up to 20 min. The concentration of saline solution was increased at intervals of 10 min from 3 to 4%. FEV 1 was measured every 5 min during inhalation. The sputum induction procedure did not cause troublesome symptoms, and the FEV 1 did not decrease by Ͼ 20% in any patient. Every 5 min, patients were asked to try to cough sputum into a Petri dish and to collect saliva in a separate container. Plugs free of salivary contamination were suspended in a dithiothreitol solution (0.1%) and were incubated for 30 min at 37°C for slide making. Cells were centrifuged at 400g for 10 min and then were resuspended in saline solution. Three sputum slides then were prepared for cytologic examination by cytocentrifugation. Cells were air dried and stained with May-GrunwaldGiemsa stain. Cell differentials were determined by counting 200 nonsquamous cells on each sputum slide. All of the sputum samples were collected from patients as induced sputum. Ninetyone patients were able to produce adequate sputum samples to perform the differential cell count.
Protocol
Spirometry and sputum induction were performed on day 1. Twenty-four hours later, each patient underwent a methacholine bronchoprovocation test.
Data Analysis
The PC 20 was logarithmically transformed for statistical analysis. Linear regression analysis for parametric and nonparametric statistics was applied when appropriate to assess the relationship between the dyspnea score and the reduction in FEV 1 .
PD was assessed as slopes and intercepts of changes in VAS on FEV 1 decreases as the percentage of the predicted value and as PD at 5 to 20% of the lowest decrease in FEV 1 after saline solution inhalation. The PD 20 was defined as the perception of dyspnea when FEV 1 decreased by 20% from that after inhalation of saline solution.
The differences between the four subgroups were evaluated by using analysis of variance and univariate analysis of variance for repeated measures (ie, split plot) 26 when appropriate. The Bonferroni test was used for comparisons between subgroups.
Factor analysis was used to determine the dimensions underlying the pattern of interrelationships. 27 Factor analysis is a statistical technique applied to a single set of variables to discover which sets of variables form coherent subsets that are relatively independent of one another. Variables that are correlated with one another, which are also largely independent of other subsets of variables, are combined into factors. The purpose of the analysis is to obtain a small number of factors that account for most of the variability in the variables. Accordingly, it is important to recognize that factor analysis does not merely regroup variables that are highly correlated with one another. In the final solution, correlations are obtained among all variables entered in the analysis and the virtual factors. Each of the original variables employed in the analysis are said to load on the factors, to a greater or lesser extent, based on the magnitude of the obtained correlations between each variable and the factor. In general, each variable loads (ie, is correlated most highly with) a single factor. Factors are labeled, conveniently, in terms of the pattern of these loadings.
Thus, the purpose of using factor analysis in the present study was to determine whether, in clinically stable asthma patients, PD, respiratory function, BHR, and airway inflammation would reduce to similar or different factors. To determine the number of factors we should extract, we employed a combination of methods.
The possibility of performing the factor analysis was tested by means of Bartlett's test of sphericity. Details of the method have been thoroughly discussed elsewhere. 28 *Values given as mean Ϯ SD (range). †au ϭ arbitrary units.
Results
Anthropometric, clinical, baseline function, and sputum data of the four groups of patients are listed in Tables 1 and 2 . Groups were matched ( 2 analysis) for age, gender, atopy, and clinical score. Groups I and III also were matched for duration of the disease, and groups II and IV were matched for duration of the disease and the daily dosage of ICSs. In groups II and IV, the duration of the disease was significantly higher than that in groups I and III.
Analysis of Variance
VC was smaller in group I than in groups II and III, functional residual capacity was greater in group II than in group IV, and PC 20 was greater in group IV than in group I ( Table 2) . Table 3 shows slopes and intercepts for the change in VAS associated with change in FEV 1 . For each subject, we observed a significant linear correlation (r Ͼ 0.7) between the decrease in FEV 1 , expressed as a percentage of the predicted value, and the concurrent score of perceived bronchoconstriction, expressed in terms of VAS (p ϭ 0.03-0.0001) during methacholine inhalation. No differences among groups in both slopes and intercepts were found with respect to whether patients were obstructed or not obstructed and were ICS-naive or ICS-treated.
When groups were compared (univariate analysis of the variance) for a 5 to 20% decrease in FEV 1 after saline solution inhalation (Fig 1) , dyspnea scores were the lowest in group II (obstructed ICS-treated patients), were slightly higher in group IV (nonobstructed ICS-treated patients), higher still in group I (obstructed ICS-naive patients), and the highest in group III (nonobstructed ICS-naive patients). In particular, group II differed from groups IV, I, and III (p Ͻ 0.000 for all comparisons); group IV differed from groups I and III (p Ͻ 0.000); and group III differed from group I (p Ͻ 0.000). In general, these data indicate that ICS-treated patients exhibited a lower PD score than ICS-naive patients, regardless of whether airway obstruction was present. In particular, the observation that PD was greater in obstructed ICS-naive patients than in nonobstructed ICS-treated patients substantiates this statement. VAS slopes (Fig 2) . This relationship was not significant in the other subgroups.
Relationships
Factor Analysis
Primary Analysis: Factor analysis was performed by including age, FEV 1 (in liters), duration of the disease, eosinophil counts, PC 20 , ICS use, daily dosage (0, 500, or 1000 g), and breathlessness on the VAS scale. The Bartlett test of sphericity showed that the variables used were correlated (approximate 2 , 103.005; degrees of freedom, 21; p ϭ 0.000). Four interpretable factors accounted for 70% of the variance in the data; the correlations with the original variables obtained for each rotated factor (factor loadings) are displayed in Table 4 . The results did not change when eosinophil counts were expressed as the total number of cells present. As shown in the table, FEV 1 and age loaded on factor I, ICSs and duration of disease loaded on factor II, slope VAS and PC 20 loaded on factor III, eosinophil counts and PC 20 were loaded on factor IV.
A further analysis was carried out by randomly dividing patients into two subgroups, including the same variables previously described in each subgroup. The subgroups were matched in terms of age, gender, lung function, sputum analysis, and BHR as indicated by the results of unpaired t tests and the 2 test carried out between subgroups. We obtained similar results for each subgroup, and the analysis was comparable to the analysis of the entire group of patients. In fact, the factor analysis yielded four factors with similar factor loadings, accounting for 79.5 of the variance in one subgroup and 78.3 in the other.
Post Hoc Analyses:
Additional analysis was conducted by dividing patients into two subgroups on the basis of ICS therapy, with the same variables included as in the primary analysis. In the post hoc analysis, ICS-naive patients were younger (p Ͻ 0.05) with no differences in eosinophil counts (p Ͼ 0.05), pulmonary function (p Ͼ 0.05), or PC 20 (p Ͼ 0.05) but with different PD (p Ͻ 0.05 to p Ͻ 0.01). In ICS-naive patients and ICS-treated patients, four and three factors, respectively, accounted for a similar percentage of the variance. Eosinophil counts were associated with PD, positively in ICS-naive patients and negatively in ICS-treated patients. PC 20 was either independent loading in ICS-naive patients or associated loading with PD in ICS-treated patients (Table 5) . In both groups, the duration of the disease was an independent loading on factor III.
Discussion
On a preliminary standard statistical approach, our data showed the following: (1) the occurrence of the lowest VAS score on acute changes in FEV 1 in ICS-treated patients (Fig 1) ; and (2) a negative relationship in obstructed ICS-treated patients between eosinophil counts and PDs (Fig 2) .
These data are in line with studies on the effect of eosinophil inflammation and ICSs 11-14 on PD. Eosinophil airway inflammation has been proposed as a determinant of breathlessness 13, 14, 29 via mechanisms affecting either the mechanical pathways that control breathlessness 5, 30 or the afferent nerves involved in PD. 13 in't Veen et al 14 have suggested that an ongoing airway inflammation characterized by eosinophilic airway infiltration, despite treatment with inhaled ICSs, was associated with a reduced perception of airflow obstruction. They believe the influence of both the severity of asthma and the use of ICSs to be the most plausible explanation for the PD/eosinophil relationship. In this regard, however, it must be mentioned that the same effect of ICSs on dyspnea has been noted in studies dealing with the following different types of asthma: inadequately controlled by inhaled bronchodilator alone 12 ; severely brittle 14 ; and moderate, as in the present study. Consistent with the above data, Higgs and Laszlo 12 were able to find a reduction in the symptoms of asthma with beclomethasone (BCM) therapy without any improvement in the results of airflow tests, as shown by the fact that the slopes of Borg on peak expiratory flow were less steep when patients received BCM than when they received either cromoglycate or theophylline. However, as opposed to the results of in't Veen et al, 14 Higgs and Laszlo 12 maintained that this effect could be due to BCMinduced reduction in airway inflammation. 12 At variance, other investigators 11, 13 have reported on the positive role of ICSs on PD. Roisman et al 13 found a negative correlation between bradykinin-induced PD and the magnitude of eosinophilic inflammation in airway mucosa, but, at variance with in't Veen et al, 14 the negative relationship appears to be held by subjects who were not receiving ICSs. In contrast, subjects receiving ICSs had lower eosinophil infiltration and greater PD than those not using those agents. Boulet et al 11 have confirmed a higher symptom score for a given degree of fall in expiratory flows in patients using ICSs than patients using only bronchodilators on demand. It has been suggested 13 that the asthmatic inflammatory process with its eosinophilic airway inflammation, which is present even in the mildest cases of asthma, 15, 25 could reduce *Bold values represent the highest loadings. The square of the factor loading provides the proportion of the estimated common variance in a variable that is explained by the factor. The sum of the squared factor loadings, the eigenvalue, indicates how much the factor contributed to explaining the common variance underlying the variables. PD and is possibly due to damage to the sensory receptors in the airways. Accordingly, the increase in PD with inhaled ICS therapy may be inferred to be a result of the reduction of the inflammatory process and the restoration of the integrity of the airway epithelium. 13 In light of these discrepancies, to substantiate our data we tried to break down the relative potential contributions of eosinophil counts and ICSs to PD by applying factor analysis, which overcomes the problem of overlapping between variables. Some variables indeed share high percentages of their variation with other variables. This is the case with FEV 1 . 31 Insight also may be gained from variables that do not appear to be significantly related to others in a standard analysis, which was the case in the lack of association between VAS score and eosinophil counts in subgroups other than obstructed ICS-treated patients. For the above reasons, factor analysis can be used successfully as a data reduction technique in a clinical study of patients with multiple interrelated outcome measures that are used to characterize the disease process.
Accordingly, we first sought to determine whether the clinical characteristics of the disease, such as PD, airway obstruction, BHR, eosinophilic bronchial inflammation, or anti-inflammatory treatment, would reduce to similar or different factors in patients in stable condition with chronic asthma. As shown by the analysis, measurements of airway obstruction (factor I), ICS treatment (factor II), BHR (factor III), and eosinophil counts and PD (factor IV) remained important dimensions in the assessment of patients with chronic asthma. Furthermore, to better define the potential effect of the association of ICSs with eosinophil counts on PD, in the post hoc analysis ICS-naive patients were separated from ICS-treated patients. The data indicate that eosinophil counts were associated with PD, positively in the former group and negatively in the latter group. The positive association of eosinophil counts with PD in ICS-naive patients is consistent with the data by in't Veen et al. 14 The inverse association of eosinophil counts with PD in ICS-treated patients, also reported by the same authors, 14 implies that the ICS-eosinophil blend may result in deteriorating PDs.
However, it is worth noting that in the present study, as in other studies, airway eosinophil inflammation was assessed by measuring eosinophil counts in induced sputum samples. This might explain the differences with another report 13 that assessed the inflammatory cell population in the asthmatic bronchial mucosa. One could note that in the studies by in't Veen et al 14 and Roisman et al, 13 unlike in our study, airway eosinophil inflammation did not significantly relate to the dyspnea sensitivity associated with methacholine-induced bronchoconstriction. Discrepancies between their and our results may simply be due to differences in the number of patients and their clinical characteristics.
Attempts to relate PD to BHR have shown that patients with high responsiveness to histamine perceive less bronchoconstriction than less responsive subjects. 6 However, the relationship between PC 20 and breathlessness was weak in the study by Burdon et al, 6 and further studies on the same topic 9,11,12 did not confirm those results. Our data, indicating that PD related to BHR in the patients as a group, are only in part in line with the study by Burdon et al 6 in which the effect of ICS therapy was not taken into account. In the present study, indeed, PD was associated with BHR in ICS-treated patients but was independent of BHR in ICS-naive patients. Thus, whether they were obstructed or nonobstructed, ICS-treated and ICS-naive patients had similar PC 20 values, which casts some doubts on the association of BHR with PD found in the data in Table 4 . The present data therefore do not permit us to share the effects of ICSs and BHR on PD.
As found in previous articles both by us 7 and others, 32 in neither group reported on in the present study was baseline airway obstruction associated with PD or PC 20. Significant individual variability in PD was observed, with some patients showing reduced ventilatory function without dyspnea and others evidently dyspneic with minimal ventilatory impairment. Although the explanation of this is likely to be complex, one might consider that dyspnea has an important affective dimension and often evokes emotional and behavioral responses that can vary among patients. 33 Some subjects are more fearful than others, leading to anxiety and an exaggerated response; others are fearless and have an insufficient response.
That ICSs may have a direct effect at the level of the CNS in asthma patients has not been excluded. 12, 14 In this regard, it has been postulated that a central effect 34 of ICSs on symptom severity via the inhibition of adrenocorticotropic hormone secretion 35 results in a reduced sensory acuity in human beings. 36 Our data seem to be in favor of an associated effect of eosinophil counts with ICSs rather than an effect of ICSs, per se, on PD.
In summary, we have shown that eosinophilic inflammation of the airway wall may increase PD and that the association of eosinophil counts with ICS may result in lessening the PD. It is worthwhile noting the importance of this information for patients in whom reduced awareness of symptoms could delay the assumption of rescue treatment.
